Please provide your email address to receive an email when new articles are posted on . CVS Caremark, one of the nation’s largest pharmacy benefit managers, will remove Humira from its major national ...
(Reuters) - CVS Health said on Wednesday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of April 1, and will ...
SPRINGFIELD, Mass. (WWLP) – Health New England announced Monday that it will shift coverage of the biologic drug Humira to more affordable FDA-approved biosimilars starting next month for members of ...
(Reuters) - AbbVie’s top-selling arthritis drug Humira has held onto more than 80% of patients after facing nine lower-priced rivals in the U.S. in the last year, raising questions about whether the ...
The biggest U.S. drug benefits manager is making a move that will take a bite out of sales for the world’s top-selling medication. CVS Health Corp. will remove AbbVie’s Humira from most of its lists ...
A major California health plan has struck a novel deal directly with a drug manufacturer for a cheaper version of Humira, cutting out pharmacy benefit managers — controversial middlemen in the drug ...
Rise and shine, everyone, another busy day is on the way. Sadly, gray skies are hovering over the Pharmalot campus right now, but our spirits remain sunny, nonetheless. Why? We will draw on a bit of ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The first Humira biosimilar hit the U.S. market a little ...
UnitedHealth Group's Optum Rx will join its peers in the big three pharmacy benefit managers by pulling Humira from some of its preferred formularies, according to a report from Reuters. Instead, it ...
Meitheal, a biopharmaceutical company focused on developing and commercializing generic injectables, fertility, biologic and branded products, has gained exclusive U.S. commercial rights to Yusimry, a ...
Look into AbbVie's strategy a company built around its blockbuster Humira, now diversifying its pipeline after the patent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results